Cytogenetic evolution of human ovarian cell lines associated with chemoresistance and loss of tumorigenicity

被引:4
作者
Struski, S
Doco-Fenzy, M
Koehler, M
Chudoba, I
Levy, F
Masson, L
Michel, N
Ulrich, E
Gruson, N
Bénard, J
Potron, G
Cornillet-Lefebvre, P
机构
[1] Hop Robert Debre, Hematol Lab, F-51100 Reims, France
[2] Fac Med, UPRES EA 20 70, IFR Biomol 53, F-51100 Reims, France
[3] Maison Blanche Hosp, Lab Cytogenet, F-51100 Reims, France
[4] ASI GmbH, D-68309 Mannheim, Germany
[5] MetaSyst, D-68804 Altlussheim, Germany
[6] Polytec Pl, Electroopt Div, F-93694 Pantin, France
[7] Inst Gustave Roussy, F-94800 Villejuif, France
来源
ANALYTICAL CELLULAR PATHOLOGY | 2003年 / 25卷 / 03期
关键词
D O I
10.1155/2003/151042
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to identify genomic changes associated with a resistant phenotype acquisition, we used comparative genomic hybridization (CGH) to compare a human ovarian cell line, Igrov1, and four derived subcell lines, resistant to vincristine and presenting a reversion of malignant properties. Multicolor FISH (Multiplex-FISH and Spectral Karyotype) and conventional FISH are also used to elucidate the karyotype of parental cell line. The drug-resistant subcell lines displayed many chromosomal abnormalities suggesting the implication of different pathways leading to a multidrug resistance phenotype. However, these cell lines shared two common rearrangements: an unbalanced translocation der(8)t(8;13)(p22;q?) and a deletion of the 11p. These chromosomal imbalances could reflected the acquisition of the chemoresistance (der(8)) or the loss of tumorigenicity properties (del(11p)). Colour figure can be viewed on http://www.esacp.org/acp/2003/25-3/struski.htm.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 36 条
[1]  
Baggetto LG, 1997, B CANCER, V84, P385
[2]  
BENARD J, 1985, CANCER RES, V45, P4970
[3]   OVER-EXPRESSION OF MDR1 GENE WITH NO DNA AMPLIFICATION IN A MULTIPLE-DRUG-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINE [J].
BENARD, J ;
DASILVA, J ;
TEYSSIER, JR ;
RIOU, G .
INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (03) :471-477
[4]  
Coleman WB, 1999, INT J ONCOL, V14, P957
[5]  
DODSON MK, 1993, CANCER RES, V53, P4456
[6]  
DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638
[7]   LOSS OF HETEROZYGOSITY IN CERVICAL-CARCINOMA - SUBCHROMOSOMAL LOCALIZATION OF A PUTATIVE TUMOR-SUPPRESSOR GENE TO CHROMOSOME 11Q22-Q24 [J].
HAMPTON, GM ;
PENNY, LA ;
BAERGEN, RN ;
LARSON, A ;
BREWER, C ;
LIAO, S ;
BUSBYEARLE, RMC ;
WILLIAMS, AWR ;
STEEL, CM ;
BIRD, CC ;
STANBRIDGE, EJ ;
EVANS, GA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (15) :6953-6957
[8]   LOSS OF TUMORIGENICITY IN A METHOTREXATE-RESISTANT HUMAN LEUKEMIA-CELL LINE [J].
HILL, AB ;
TRENT, JM ;
THOMPSON, FH ;
DANKS, MK ;
BECK, WT .
CANCER GENETICS AND CYTOGENETICS, 1993, 70 (01) :48-55
[9]  
Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO
[10]  
2-#